04-12-2007, 01:07 PM
A treatment involving the transplant of a patient's own stem cells, also known as autologous transplant or self-transplant, could help to reduce or eliminate the need for insulin in people with type one diabetes (formerly known as childhood or insulin dependent diabetes), a new study claims.
Writing in the Journal of the American Medical Association (JAMA), April 11, 2007, the researchers describe the results as "very encouraging".
"Further follow-up is necessary to confirm the duration of insulin independence and the mechanisms of action of the procedure," they add.
"In addition, randomised controlled trials and further biological studies are necessary to confirm the role of this treatment in changing the natural history of type one [diabetes] and to evaluate the contribution of hematopoietic [blood] stem cells to this change."
The study focused on 15 newly diagnosed patients, aged 14 to 31. The American and Brazilian researchers removed stem cells from the patients' blood and stored them in liquid nitrogen.
Then the 15 people were treated with a high dose of immunosuppresors to prevent further destruction of their pancreatic cells responsible for insulin production, effectively destroying faulty the immune-system cells. In type 1 diabetes, a person’s immune system attacks and destroys insulin-producing beta cells in the pancreas. Preserving beta cells is a key concept in the management of type 1 diabetes.
Then the researchers treated stem cells from the patients' blood and then injected them back into the bloodstream. This transplant of blood stem cells is called "autologous nonmyeloablative hematopoietic stem cell transplantation", or AHST. These patient's own stem cells replace the defective cells that cause the disease. Patients spend about three weeks in the hospital and experience problematic chemotherapy side effects such as nausea, hair loss and possible infertility. There's a calculated 1 in 200 chance of dying, although fortunately there were no deaths in the study.
The researchers found that 14 patients became insulin free, one for 35 months while another four were insulin free for at least 21 months, seven for at least six months and two with late response were insulin-free for one and five months respectively.
Lead author Dr. Julio C. Voltarelli, from the Regional Blood Centre in Ribeiro Preto, Brazil, called these results "very encouraging". The type 1 form of diabetes accounts for 5 to 10 percent of the approximately 21 million Americans with the disease.
"For the first time in the history of diabetes, patients are now treatment-free for up to three years," says Dr. Richard Burt, the senior author of the study and chief of the division of immunotherapy at Northwestern University's Feinberg School of Medicine. playfuls.com
Writing in the Journal of the American Medical Association (JAMA), April 11, 2007, the researchers describe the results as "very encouraging".
"Further follow-up is necessary to confirm the duration of insulin independence and the mechanisms of action of the procedure," they add.
"In addition, randomised controlled trials and further biological studies are necessary to confirm the role of this treatment in changing the natural history of type one [diabetes] and to evaluate the contribution of hematopoietic [blood] stem cells to this change."
The study focused on 15 newly diagnosed patients, aged 14 to 31. The American and Brazilian researchers removed stem cells from the patients' blood and stored them in liquid nitrogen.
Then the 15 people were treated with a high dose of immunosuppresors to prevent further destruction of their pancreatic cells responsible for insulin production, effectively destroying faulty the immune-system cells. In type 1 diabetes, a person’s immune system attacks and destroys insulin-producing beta cells in the pancreas. Preserving beta cells is a key concept in the management of type 1 diabetes.
Then the researchers treated stem cells from the patients' blood and then injected them back into the bloodstream. This transplant of blood stem cells is called "autologous nonmyeloablative hematopoietic stem cell transplantation", or AHST. These patient's own stem cells replace the defective cells that cause the disease. Patients spend about three weeks in the hospital and experience problematic chemotherapy side effects such as nausea, hair loss and possible infertility. There's a calculated 1 in 200 chance of dying, although fortunately there were no deaths in the study.
The researchers found that 14 patients became insulin free, one for 35 months while another four were insulin free for at least 21 months, seven for at least six months and two with late response were insulin-free for one and five months respectively.
Lead author Dr. Julio C. Voltarelli, from the Regional Blood Centre in Ribeiro Preto, Brazil, called these results "very encouraging". The type 1 form of diabetes accounts for 5 to 10 percent of the approximately 21 million Americans with the disease.
"For the first time in the history of diabetes, patients are now treatment-free for up to three years," says Dr. Richard Burt, the senior author of the study and chief of the division of immunotherapy at Northwestern University's Feinberg School of Medicine. playfuls.com
